Piotr Stępień

Mr. Piotr Stępień

Uniwersytet Jana Kochanowskiego w Kielcach
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2022 in Viruses
Verified
Journal Article
Open access
PDF file
PPPaweł Pabjan
Paweł Pabjan
MBMichał Brzdęk
Michał Brzdęk
MCMagdalena Chrapek
Magdalena Chrapek
KDKacper Dziedzic
Kacper Dziedzic
Krystyna DobrowolskaKrystyna Dobrowolska
Krystyna Dobrowolska
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
Difficult-to-treat populations with chronic hepatitis C (CHC), in the era of interferon treatment, included patients with liver cirrhosis, kidney impairment, treatment-experienced individuals, and those coinfected with the human immunodeficiency virus. The current study aimed to determine whether, in the era of direct-acting antivirals (DAA), there are still patients that are difficult-to-treat. The study included all consecutive patients chronically infected with hepatitis C virus (HCV) who started interferon-free therapy between July 2015 and December 2020 in the Department of Infectious Diseases in Kielce. The analyzed real-world population consisted of 963 patients, and most of them were infected with genotype 1 (87.6%) with the predominance of subtype 1b and were treatment-naïve (78.8%). Liver cirrhosis was determined in 207 individuals (21.5%), of whom 82.6% were compensated. The overall sustained virologic response, after exclusion of non-virologic failures, was achieved in 98.4%. The univariable analysis demonstrated the significantly lower response rates in males, patients with liver cirrhosis, decompensation of hepatic function at baseline, documented esophageal varices, concomitant diabetes, body mass index ≥25, and previous ineffective antiviral treatment. Despite an overall very high effectiveness, some unfavorable factors, including male gender, genotype 3 infection, liver cirrhosis, and treatment experience, significantly reduce the chances for a virologic response were identified.

Verified
Journal Article
Open access
PDF file
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
JJJerzy Jaroszewicz
Jerzy Jaroszewicz
APAnna Parfieniuk-Kowerda
Anna Parfieniuk-Kowerda
EJEwa Janczewska
Ewa Janczewska
DDDorota Dybowska
Dorota Dybowska
Robert FlisiakRobert Flisiak
Robert Flisiak
There is still limited data available from real-world experience studies on the pangenotypic regimens in patients with genotype (GT) 3 hepatitis C virus (HCV) infection and liver cirrhosis. The current study aimed to evaluate the efficacy and safety of pangenotypic regimens in this difficult-to-treat population. A total of 236 patients with mean age 52.3 ± 11.3 years and male predominance (72%) selected from EpiTer-2 database were included in the analysis; 72% of them were treatment-naïve. The majority of patients (55%) received the combination of sofosbuvir/velpatasvir (SOF/VEL), 71 without and 58 with ribavirin (RBV), whereas the remaining 107 individuals were assigned to glecaprevir/pibrentasvir (GLE/PIB). The effectiveness of the treatment following GLE/PIB and SOF/VEL regimens (96% and 93%) was higher compared to SOF/VEL + RBV option (79%). The univariate analysis demonstrated the significantly lower sustained virologic response in males, in patients with baseline HCV RNA ≥ 1,000,000 IU/mL, and among those who failed previous DAA-based therapy. The multivariate logistic regression analysis recognized only the male gender and presence of ascites at baseline as the independent factors of non-response to treatment. It should be emphasized that despite the availability of pangenotypic, strong therapeutic options, GT3 infected patients with cirrhosis still remain difficult-to-treat, especially those with hepatic impairment and DAA-experienced.

1 January 2015 in Clinical and Experimental Hepatology
Verified
Journal Article
Open access
PSPiotr Stępień
Piotr Stępień
KRKatarzyna Reczko
Katarzyna Reczko
AWAnna Wieczorek
Anna Wieczorek
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
PPPaweł Pabjan
Paweł Pabjan
WKWiesław Kryczka
Wiesław Kryczka
Stanozolol is a 17α-alkylated synthetic anabolic steroid used illegally by bodybuilders. We present a 19-year-old man who was taking 50 mg of stanozolol intramuscularly, every other day for 2 months, to improve muscle mass. On admission, his bilirubin concentration was 44.34 mg/dl. The serum...

1 January 2013
Verified
Journal Article
Closed access
APAnatol Panasiuk
Anatol Panasiuk
Robert FlisiakRobert Flisiak
Robert Flisiak
IMIwona Mozer-Lisewska
Iwona Mozer-Lisewska
AAAgnieszka Adamek
Agnieszka Adamek
MTMałgorzata Tyczyno
Małgorzata Tyczyno
ALAnna Lachowicz
Anna Lachowicz

1 January 2017 in Clinical and Experimental Hepatology
Verified
Journal Article
Open access
PDF file
AWAnna Wieczorek
Anna Wieczorek
PSPiotr Stępień
Piotr Stępień
Dorota Zarębska-MichalukDorota Zarębska-Michaluk
Dorota Zarębska-Michaluk
WKWiesław Kryczka
Wiesław Kryczka
PPPaweł Pabjan
Paweł Pabjan
TKTeodora Król
Teodora Król
Although chronic hepatitis C virus (HCV) infection affect 185 million people world-wide, pathomechanism of liver damage is still unclear. Electron microscopy can reveal liver injury in very early stage and help understanding the mechanisms that is crucial in the pathogenesis of chronic hepatitis...

31 March 2016 in Baltic Journal of Health and Physical Activity
Verified
Journal Article
Open access
Zbigniew JastrzębskiZbigniew Jastrzębski
Zbigniew Jastrzębski
Łukasz RadzimińskiŁukasz Radzimiński
Łukasz Radzimiński
PSPiotr Stępień
Piotr Stępień